Home » Research Area » Respiratory Disease Research » 7-TM Receptors » GABA_B Receptors » CGP 54626 hydrochloride

CGP 54626 hydrochloride

Cat. No. 1088

Price and Availability

For CGP 54626 hydrochloride pricing & availability please select your country from the drop down menu:
Submit

By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Chemical Name: [S-(R*,R*)]-[3-[[1-(3,4-Dichlorophenyl)ethyl]amino]-2-hydroxypropyl](cyclohexylmethyl) phosphinic acid

Biological Activity

A potent, selective GABA_B receptor antagonist (IC₅₀ = 4 nM).

Licensing Information

Sold with the permission of Novartis Pharma AG

Technical Data

M.Wt:

444.76

Formula:

C₁₈H₂₈Cl₂NO₃P.HCl

Solubility:

Soluble to 100 mM in DMSO and to 10 mM in ethanol

Purity:

>96 %

Storage:

Store at RT

CAS No:

149184-21-4

The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.

Resources

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch

Safety Data Sheet: View Safety Data Sheet

References

Brugger et al (1993) The action of new potent GABA_B receptor antagonists in the hemisected spinal cord preparation of the rat. Eur.J.Pharmacol. 235 153. PMID: 8390938.

Froestl et al (1996) Potent, orally active GABA_B receptor antagonists. Pharmacol.Rev.Comm. 8 127.

Kaupmann et al (1998) GABA_B-receptor subtypes assemble into functional heteromeric complexes. Nature 396 683. PMID: 9872317.

If you know of a relevant citation for this product please let us know.

View Related Products by Target

GABA_B Receptors

Keywords: CGP 54626 hydrochloride, supplier, Potent, selective, GABAB, antagonists, Receptors, CGP54626, hydrochloride

Quick Order

Find multiple products by catalog number

Pain Research Product Guide

Highlights over 280 products for Pain research. Request copy or view PDF today.

GABA Review

Written by Ian Martin, Norman Bowery & Susan Dunn. Request a copy or view PDF today.

7-TM Receptor Signaling

Written by T. Kenakin et al

'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy

Therapeutic Strategies in Schizophrenia

Written by J. Lieberman

'Schizophrenia - Emerging Targets and Therapeutic Strategies' provides a summary of the targets and pathways representing the most promising strategies to pursue for novel drug development.